PTC Therapeutics CLO Mark Boulding sells $12,337 in stock
PTC Therapeutics' CLO Mark Boulding sold 192 shares for $12,337 and acquired 192 shares via options. PTCT shares trade near 52-week lows, down 21% YTD. Q2 2026 earnings beat estimates, with revenue at $361M. Analysts raised price targets post-acquisition of ST-920 gene therapy. InvestingPro lists PTCT as undervalued.
How this was made
The 30-second read
Why it matters
The insider sale is a new filing but its materiality is limited given the company's recent positive momentum.
Market read
Primary relevance stems from the Form 4 insider sale; broader market impact is minimal.
What to watch
Recent strong Q2 results and raised guidance may outweigh the small sell‑off, keeping the stock stable.
Background
PTCT recently reported Q2 2026 earnings that beat expectations and raised full‑year guidance. The article also mentions a recent acquisition of a gene therapy.
Ticker impact
SEC Form 4 disclosed Mark Boulding sold 192 shares of PTCT for $12,337 on Oct 9, 2026 under a 10b5‑1 plan.
potential slight downward pressure as the market digests the insider sale
The transaction size is modest relative to float and occurs after a recent earnings beat, so impact is limited.
Market effects
Minimal; the biotech sector is unlikely to move on a small insider transaction.
None; the news is company‑specific.
Low; no broader market effect.
Counterpoint
The sale could be interpreted as insider confidence if the purchase of options offsets the sale.
Key entities
- executiveMark Boulding
Executive Vice President and Chief Legal Officer of PTCT, insider filing a 10b5‑1 sale.
